ProfileGDS5678 / 1429680_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 72% 75% 73% 75% 80% 76% 76% 75% 75% 72% 76% 76% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9903175
GSM967853U87-EV human glioblastoma xenograft - Control 24.6241372
GSM967854U87-EV human glioblastoma xenograft - Control 34.9494575
GSM967855U87-EV human glioblastoma xenograft - Control 44.8794873
GSM967856U87-EV human glioblastoma xenograft - Control 54.9466275
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4301580
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9878176
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0936876
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.980375
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0444575
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6040672
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1454576
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0545776
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1679977